STERIS plc STE
STERIS is a leading global provider of products and services that support patient care with an emphasis on infection prevention. WE HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare and life science products and services around the globe. We offer our Customers a unique mix of innovative products and services. These include: consumable products, such as detergents, endoscopy accessories, barrier products, instruments and tools; services, including equipment installation and maintenance, microbial reduction of medical devices, instrument and scope repair, laboratory testing, and outsourced reprocessing; capital equipment, such as sterilizers, surgical tables, and automated endoscope reprocessors; and connectivity solutions such as operating room ("OR") integration.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.94B | $5.46B | $5.14B | $4.54B | $4.22B | $3.11B | $3.03B | $2.78B | $2.62B | $2.61B |
| Cost of revenue | $3.31B | $3.06B | $2.92B | $2.56B | $2.34B | $1.76B | $1.71B | $1.61B | $1.53B | $1.59B |
| Gross profit | $2.63B | $2.40B | $2.22B | $1.98B | $1.88B | $1.34B | $1.32B | $1.17B | $1.09B | $1.03B |
| R&D | $112.9M | $107.6M | $103.7M | $98.5M | $86.7M | $66.3M | $65.5M | $63.0M | $60.8M | $59.4M |
| SG&A | $1.41B | $1.33B | $1.25B | $1.09B | $1.32B | $731.3M | $716.7M | $669.9M | $632.0M | $682.0M |
| Total operating expenses | $1.52B | $1.54B | $1.38B | $1.19B | $1.41B | $794.7M | $783.0M | $764.0M | $692.9M | $800.0M |
| Operating income | $1.10B | $866.6M | $836.1M | $791.1M | $477.8M | $548.4M | $537.0M | $411.0M | $399.9M | $226.2M |
| Interest expense | $60.7M | $86.3M | $144.4M | $108.0M | $89.5M | $37.2M | $40.3M | $45.0M | $50.6M | $44.5M |
| Pre-tax income | $1.05B | $796.2M | $702.8M | $680.3M | $366.8M | $517.5M | $498.8M | $369.0M | $355.0M | $184.6M |
| Income tax | $262.2M | $184.7M | $149.5M | $124.1M | $82.3M | $120.7M | $90.9M | $64.3M | $63.4M | $74.0M |
| Net income | $782.3M | $614.6M | $378.2M | $107.0M | $243.9M | $397.4M | $407.7M | $303.7M | $290.9M | $110.0M |
| EPS, basic | 7.97 | 6.24 | 3.83 | 1.07 | 2.50 | 4.66 | 4.81 | 3.59 | 3.42 | 1.29 |
| EPS, diluted | 7.93 | 6.20 | 3.81 | 1.07 | 2.48 | 4.63 | 4.76 | 3.55 | 3.39 | 1.28 |
| Shares, diluted (wtd. avg.) | $98.7M | $99.1M | $99.4M | $100.2M | $98.3M | $85.9M | $85.6M | $85.5M | $85.7M | $86.1M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $439.6M | $171.7M | $207.0M | $208.4M | $348.3M | $220.5M | $319.6M | $220.6M | $201.5M | $282.9M |
| Receivables | $1.09B | $1.04B | $1.01B | $865.0M | $799.0M | $609.4M | $586.5M | $564.8M | $528.1M | — |
| Inventory | $631.8M | $581.3M | $674.5M | $604.4M | $575.0M | $315.1M | $263.5M | $208.2M | $205.7M | — |
| Total current assets | $2.39B | $2.00B | $2.87B | $2.01B | $1.88B | $1.21B | $1.22B | $1.05B | $989.7M | — |
| Property, plant and equipment | $2.16B | $1.96B | $1.77B | $1.63B | $1.55B | $1.24B | $1.11B | $1.03B | $1.01B | — |
| Goodwill | $4.19B | $4.10B | $4.07B | $3.88B | $3.94B | $3.03B | $2.36B | $2.32B | $2.43B | $2.23B |
| Other intangibles | $1.62B | $1.85B | $2.12B | $2.08B | $3.33B | $898.4M | $565.5M | $604.6M | $727.0M | — |
| Total assets | $10.74B | $10.15B | $11.06B | $10.82B | $11.42B | $6.57B | $5.44B | $5.07B | $5.20B | — |
| Accounts payable | $338.8M | $280.8M | $251.7M | $264.2M | $225.7M | $156.9M | $149.3M | $152.9M | $135.9M | — |
| Short-term debt | $118.9M | $125.0M | $85.9M | $60.0M | $142.9M | $0 | — | — | — | — |
| Total current liabilities | $1.15B | $1.02B | $931.1M | $861.8M | $922.2M | $577.9M | $503.6M | $465.2M | $398.5M | — |
| Long-term debt | $1.81B | $1.92B | $3.12B | $3.02B | $2.95B | $1.65B | $1.15B | $1.18B | $1.32B | — |
| Total liabilities | $3.54B | $3.53B | $4.75B | $4.73B | $4.88B | $2.68B | $2.02B | $1.89B | $1.98B | — |
| Retained earnings | $3.02B | $2.48B | $2.09B | $1.91B | $2.00B | $1.94B | $1.66B | $1.34B | $1.15B | — |
| Total equity | $7.18B | $6.60B | $6.32B | $6.09B | $6.54B | $3.89B | $3.42B | $3.20B | $3.22B | $2.81B |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $1.34B | $1.15B | $973.3M | $756.9M | $684.8M | $689.6M | $590.6M | $539.5M | $457.6M | $424.1M |
| Depreciation and amortisation | $486.5M | $476.2M | $565.2M | $552.9M | $553.1M | $219.2M | $197.2M | $225.9M | $178.3M | $188.1M |
| Stock-based compensation | $61.7M | $57.4M | $56.5M | $39.0M | $57.7M | $26.0M | $23.8M | $24.0M | $22.2M | $18.8M |
| Capital expenditure | $369.0M | $370.1M | $360.3M | $362.0M | $287.6M | $239.3M | $214.5M | $189.7M | $165.5M | $172.9M |
| Investing cash flow | -$512.5M | $388.8M | -$887.4M | -$383.3M | -$666.6M | -$1.15B | -$319.7M | -$213.2M | -$203.8M | -$104.3M |
| Financing cash flow | -$568.2M | -$1.57B | -$85.2M | -$498.7M | $115.8M | $345.6M | -$163.1M | -$294.8M | -$356.2M | -$267.1M |
| Dividends paid | $241.8M | $219.9M | $200.6M | $183.5M | $163.2M | $133.8M | $123.0M | $112.5M | $102.9M | $93.2M |
| Buybacks | $235.5M | $211.3M | $11.8M | $308.6M | $55.8M | $14.6M | $51.2M | $81.5M | $65.5M | $97.5M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-267599.
Others in SIC 3842
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| ISRG | INTUITIVE SURGICAL INC | $129.55B | 46.6x | 20.5% |
| EW | Edwards Lifesciences Corp | $51.82B | 49.1x | 11.5% |
| ZBH | ZIMMER BIOMET HOLDINGS, INC. | $18.71B | 27.6x | 7.2% |
| ALGN | ALIGN TECHNOLOGY INC | $11.27B | 28.1x | 0.9% |
| MSA | MSA Safety Inc | $7.28B | 26.6x | 3.7% |
| ESTA | ESTABLISHMENT LABS HOLDINGS INC. | $2.21B | — | 27.1% |
| CDRE | Cadre Holdings, Inc. | $1.27B | 29.2x | 7.5% |
| ENOV | Enovis CORP | $1.07B | — | 6.7% |